Your browser doesn't support javascript.
loading
Infection Exposure Promotes ETV6-RUNX1 Precursor B-cell Leukemia via Impaired H3K4 Demethylases.
Rodríguez-Hernández, Guillermo; Hauer, Julia; Martín-Lorenzo, Alberto; Schäfer, Daniel; Bartenhagen, Christoph; García-Ramírez, Idoia; Auer, Franziska; González-Herrero, Inés; Ruiz-Roca, Lucia; Gombert, Michael; Okpanyi, Vera; Fischer, Ute; Chen, Cai; Dugas, Martin; Bhatia, Sanil; Linka, René Martin; Garcia-Suquia, Marta; Rascón-Trincado, María Victoria; Garcia-Sanchez, Angel; Blanco, Oscar; García-Cenador, Maria Begoña; García-Criado, Francisco Javier; Cobaleda, César; Alonso-López, Diego; De Las Rivas, Javier; Müschen, Markus; Vicente-Dueñas, Carolina; Sánchez-García, Isidro; Borkhardt, Arndt.
Afiliação
  • Rodríguez-Hernández G; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain.
  • Hauer J; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Martín-Lorenzo A; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
  • Schäfer D; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain.
  • Bartenhagen C; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • García-Ramírez I; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
  • Auer F; Department of Computer Science, Bonn-Rhein-Sieg University of Applied Sciences, Sankt Augustin, Germany.
  • González-Herrero I; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain.
  • Ruiz-Roca L; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Gombert M; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
  • Okpanyi V; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain.
  • Fischer U; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Chen C; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain.
  • Dugas M; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Bhatia S; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
  • Linka RM; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
  • Garcia-Suquia M; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
  • Rascón-Trincado MV; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
  • Garcia-Sanchez A; Department of Computer Science, Bonn-Rhein-Sieg University of Applied Sciences, Sankt Augustin, Germany.
  • Blanco O; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
  • García-Cenador MB; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
  • García-Criado FJ; Departamento de Ciencias Biomédicas y del Diagnóstico, Área de Obstetricia y Ginecología, HUS-Universidad de Salamanca, Salamanca, Spain.
  • Cobaleda C; Departamento de Ciencias Biomédicas y del Diagnóstico, Área de Obstetricia y Ginecología, HUS-Universidad de Salamanca, Salamanca, Spain.
  • Alonso-López D; Departamento de Ciencias Biomédicas y del Diagnóstico, Área de Obstetricia y Ginecología, HUS-Universidad de Salamanca, Salamanca, Spain.
  • De Las Rivas J; IBSAL, Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain.
  • Müschen M; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Vicente-Dueñas C; Departamento de Anatomía Patológica, Universidad de Salamanca, Salamanca, Spain.
  • Sánchez-García I; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Borkhardt A; Departamento de Cirugía, Universidad de Salamanca, Salamanca, Spain.
Cancer Res ; 77(16): 4365-4377, 2017 08 15.
Article em En | MEDLINE | ID: mdl-28630052
ABSTRACT
ETV6-RUNX1 is associated with the most common subtype of childhood leukemia. As few ETV6-RUNX1 carriers develop precursor B-cell acute lymphocytic leukemia (pB-ALL), the underlying genetic basis for development of full-blown leukemia remains to be identified, but the appearance of leukemia cases in time-space clusters keeps infection as a potential causal factor. Here, we present in vivo genetic evidence mechanistically connecting preleukemic ETV6-RUNX1 expression in hematopoetic stem cells/precursor cells (HSC/PC) and postnatal infections for human-like pB-ALL. In our model, ETV6-RUNX1 conferred a low risk of developing pB-ALL after exposure to common pathogens, corroborating the low incidence observed in humans. Murine preleukemic ETV6-RUNX1 pro/preB cells showed high Rag1/2 expression, known for human ETV6-RUNX1 pB-ALL. Murine and human ETV6-RUNX1 pB-ALL revealed recurrent genomic alterations, with a relevant proportion affecting genes of the lysine demethylase (KDM) family. KDM5C loss of function resulted in increased levels of H3K4me3, which coprecipitated with RAG2 in a human cell line model, laying the molecular basis for recombination activity. We conclude that alterations of KDM family members represent a disease-driving mechanism and an explanation for RAG off-target cleavage observed in humans. Our results explain the genetic basis for clonal evolution of an ETV6-RUNX1 preleukemic clone to pB-ALL after infection exposure and offer the possibility of novel therapeutic approaches. Cancer Res; 77(16); 4365-77. ©2017 AACR.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B / Proteínas de Fusão Oncogênica / Subunidade alfa 2 de Fator de Ligação ao Core / Histona Desmetilases Idioma: En Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B / Proteínas de Fusão Oncogênica / Subunidade alfa 2 de Fator de Ligação ao Core / Histona Desmetilases Idioma: En Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Espanha